Page 24 - Dr Stephanie Seneff - Reviewing Some Possible Unintended Consequences of the mRNA Vaccines Against COVID - 19
P. 24
forms of RNA found in the commercially manufactured products than in the products used in
clinical trials. The latter were produced via a much more tightly controlled manufacturing process.
Pfizer claims the RNA fragments “likely… will not result in expressed proteins” due to their
assumed rapid degradation within the cell. No data was presented to rule out protein expression,
though, leaving the reviewers to comment, “These [fragmented RNA] forms are poorly
characterised, and the limited data provided for protein expression do not fully address the
uncertainties relating to the risk of translating proteins/peptides other than the intended spike
protein” (EMA 2020). To our knowledge no data has been forthcoming since that time.
While we are not asserting that non-spike proteins generated from fragmented RNA would be
misfolded or otherwise pathological, we believe they would at least contribute to the cellular stress
that promotes prion-associated conformational changes in the spike protein that is present.
1. Lessons from Parkinson’s Disease
Parkinson’s disease is a neurodegenerative disease associated with Lewy body deposits in the brain,
and the main protein found in these Lewy bodies is α-synuclein. That protein, α-Synuclein, is
certainly prion-like insofar as under certain conditions it aggregates into toxic soluble oligomers and
fibrils (Lema Tomé et al., 2013). Research has shown that misfolded α-synuclein can form first in the
gut and then travel from there to the brain along the vagus nerve, probably in the form of exosomes
released from dying cells where the misfolded protein originated (Kakarla et al., 2020; Steiner et al.,
2011). The cellular conditions that promote misfolding include both an acidic pH and high
expression of inflammatory cytokines. It is clear that the vagus nerve is critical for transmission of
misfolded proteins to the brain, because severance of the vagus nerve protects from Parkinson’s.
Vagus nerve atrophy in association with Parkinson’s disease provides further evidence of the
involvement of the vagus nerve in transport of misfolded α-synuclein oligomers from the gut to the
brain (Walter et al., 2018). Another pathway is through the olfactory nerve, and a loss of a sense of
smell is an early sign of Parkinson’s disease. Ominously, diminution or loss of the sense of smell is
also a common symptom of SARS-CoV-2 infection.
There are many parallels between α-synuclein and the spike protein, suggesting the possibility of
prion-like disease following vaccination. We have already shown that the mRNA in the vaccine ends
up in high concentrations in the liver and spleen, two organs that are well connected to the vagus
nerve. The cationic lipids in the vaccine create an acidic pH conducive to misfolding, and they also
induce a strong inflammatory response, another predisposing condition.
Germinal centers are structures within the spleen and other secondary lymphoid organs where
follicular dendritic cells present antigens to B cells, which in turn perfect their antibody response.
Researchers have shown that mRNA vaccines, in contrast with recombinant protein vaccines, elicit a
robust development of neutralizing antibodies at these germinal centers in the spleen (Lederer et al.,
2020). However, this also means that mRNA vaccines induce an ideal situation for prion formation
from the spike protein, and its transport via exosomes along the vagus nerve to the brain.
Studies have shown that prion spread from one animal to another first appears in the lymphoid
tissues, particularly the spleen. Differentiated follicular dendritic cells are central to the process, as
they accumulate misfolded prion proteins (Al-Dybiat et al., 2019). An inflammatory response
International Journal of Vaccine Theory, Practice, and Research 2(1), May 10, 2021 Page | 412